Targeting epidermal growth factor receptor (EGFR), monoclonal antibodies cetuximab and panitumumab are effective therapeutics [3, 4] that shrink tumors for resectability [5–7] or relieve symptoms from unresectable masses by repressing tumor growth [8–10]. This evidence concerns the gene EGFR and neoplasm.